Risk of impairment, valuation losses and business restructuring due to failure to achieve growth targets
First written in FY2021. 13 of 17 entries say "Materialised", first in FY2023-Q1. Latest entry: 2026-10-10.
Terumo moved to the "Worse" side of this theme in 2022, the same year as the typical company in this theme.
The whole theme swung hardest in 2019: 10 of 27 companies on the "Worse" side.
26 other companies' latest entry also says "Materialised".
- 2026-10-08MaterialisedOccurring Fact
「The financial impact associated with this matter is currently expected to be a total loss of approximately US$610 million (approximately ¥97.5 billion).」
Following the termination of the agreement with a major customer, a review of future revenue plans is expected to result in an impairment loss of approximately ¥72.0 billion on related assets, along with approximately ¥25.5 billion in business losses, contract termination costs and business reorganization expenses during the transition period. The risk of declining asset values associated with failure to achieve growth targets and business reorganization has become more specific. The canonical thread itself remains unchanged. - FY2026MaterialisedAnnual report
「The impairment loss of ¥11,363 million recognized during the current consolidated fiscal year was mainly attributable to the following factors.」
The risk of declining asset values associated with the growth outlook and business restructuring continued, and impairment losses of ¥11,363 million were recognized due to the termination of an exclusive distribution rights agreement, cancellation of a project to improve profitability, and discontinuation of development of the aortic and cardiovascular businesses, among other factors. - 2026-05-15MaterialisedFinancial results
「The impairment loss of ¥11,363 million recognized during the current consolidated fiscal year was mainly attributable to the following factors.」
The Company recorded impairment losses associated with the termination of an exclusive distribution agreement, the discontinuation of a profitability improvement project, and the discontinuation of certain product development activities. - FY2026-H1MaterialisedAnnual report
「The impairment loss of ¥4,530 million recognized during the current interim consolidated accounting period was mainly attributable to the following reason. (Review of the agreement for exclusive distribution rights for the interventional systems business held by a subsidiary in the Americas) During the current interim consolidated accounting period, an impairment loss of ¥4,380 million was recognized because the agreement concerning exclusive distribution rights belonging to the Cardiovascular Company was terminated following a review of the partnership structure.」
Termination of the exclusive distribution rights agreement following a review of the partnership structure resulted in an impairment loss of ¥4,380 million. The risk of declining asset values associated with the growth outlook and business restructuring materialized again in FY2026-H1. - FY2025WorsenedAnnual report
「The impairment loss of ¥22,461 million recognized during the current consolidated fiscal year was mainly attributable to the following reasons.」
The decline in asset values associated with failure to achieve growth and business restructuring expanded, and impairment losses totaling ¥22,461 million were recognized in the interventional systems businesses in the Americas and Europe, the China business, contract manufacturing projects in Blood and Cell Technologies, the cardiovascular business and other areas. - FY2025-H1MaterialisedAnnual report
「The impairment loss of ¥3,530 million recognized during the current interim consolidated accounting period included an impairment loss of ¥1,246 million resulting from the decision during the period to discontinue development of certain products belonging to the Cardiovascular Company.」
Regarding the risk of declining asset values associated with the growth outlook and business restructuring, a new impairment loss of ¥1,246 million arose following the discontinuation of development of certain products belonging to the Cardiovascular Company. - FY2024MaterialisedAnnual report
「The impairment loss of ¥3,415 million recognized during the current consolidated fiscal year was mainly attributable to the following reasons. (1) Discontinuation of the use of certain production equipment: During the current consolidated fiscal year, an impairment loss of ¥1,860 million was recognized following the decision to discontinue the use of certain production equipment belonging to the Blood and Cell Technologies Company. (2) Discontinuation of certain development activities: During the current consolidated fiscal year, an impairment loss of ¥1,266 million was recognized following the decision to discontinue certain development activities belonging to the Blood and Cell Technologies Company.」
The risk of declining asset values associated with the growth outlook and business restructuring also materialized in FY2024 through impairment losses of ¥1,860 million due to the discontinuation of the use of certain production equipment in Blood and Cell Technologies and ¥1,266 million due to the discontinuation of certain development activities. - FY2024-Q3MaterialisedAnnual report
「During the third quarter of the current consolidated cumulative period, an impairment loss of ¥1,844 million was recognized following the decision to discontinue the use of certain production equipment belonging to the Blood and Cell Technologies Company.」
Regarding the risk of declining asset values associated with the growth outlook and business restructuring, a new impairment loss of ¥1,844 million arose following the decision to discontinue the use of certain production equipment belonging to the Blood and Cell Technologies Company. - FY2024-Q2RestatedAnnual report
「There were no applicable matters during the second quarter of the current consolidated cumulative period.」
Regarding impairment of non-financial assets, the Company explained that there were no applicable matters in the cumulative FY2024-Q2 period. No additional impairment of technology assets, goodwill or other assets recognized in FY2023 occurred during the period. - FY2024-Q1No impairment this quarterAnnual report
「There were no applicable matters during the first quarter of the current consolidated cumulative period.」
Regarding impairment of non-financial assets, the Company explained that, unlike the ¥1.7 billion impairment loss on technology assets recognized in the first quarter of the previous fiscal year, there were no applicable impairment matters in the first quarter of the current fiscal year. - FY2023MaterialisedAnnual report
「The impairment loss of ¥5,338 million recognized during the current consolidated fiscal year was attributable to the following reasons.」
The risk of declining asset values due to failure to achieve growth and business restructuring materialized in FY2023, with impairment losses of ¥3,563 million recognized in the in-house biologics business and ¥1,775 million on technology assets related to the discontinuation of production of certain products. - FY2023-Q3MaterialisedAnnual report
「The impairment loss of ¥5,377 million recognized during the third quarter of the current consolidated cumulative period was attributable to the following reasons. For the in-house biologics business, during the third quarter of the current consolidated cumulative period, assets held for sale and directly related liabilities were classified under an asset transfer agreement with Global Medical, and an impairment loss of ¥3,589 million was recognized in connection with measuring the disposal group at fair value less costs to sell.」
The risk of declining asset values associated with the growth outlook and business restructuring continued to materialize. In addition to an impairment loss of ¥3,589 million on the in-house biologics business, an impairment loss of ¥1,788 million on technology assets was recognized following the decision to discontinue production of certain products. - FY2023-Q2MaterialisedAnnual report
「Temporary profit or loss of negative ¥4,934 million included an impairment loss on technology assets of negative ¥1,756 million, an impairment loss on goodwill of negative ¥3,524 million, business restructuring expenses of negative ¥985 million and a ¥1,333 million change in the fair value of contingent consideration, among other items.」
An impairment loss of ¥1,756 million on technology assets, an impairment loss of ¥3,524 million on goodwill and business restructuring expenses of ¥985 million were recognized, and the risk of declining asset values associated with the growth outlook and business restructuring materialized. - FY2023-Q1MaterialisedAnnual report
「During the first quarter of the current consolidated cumulative period, as the future use of certain technology assets was no longer expected, the carrying amount of those technology assets was reduced to their recoverable amount, and an impairment loss of ¥1,699 million was recognized.」
The risk of declining asset values due to failure to achieve growth or changes in business outlook materialized through the loss of expected use of certain technology assets and recognition of a ¥1.7 billion impairment loss. - FY2021First statedAnnual report
「However, if the growth initially anticipated is not achieved, impairment of goodwill, property, plant and equipment and intangible assets, as well as gains or losses from business sales, liquidations and other events, may affect the Company's business results and financial condition.」
Disclosed the impact of impairment of goodwill and fixed assets and business sales or liquidations if growth targets are not achieved, in connection with investments based on the medium- to long-term growth strategy, as a new risk item.